Strengthening the endovascular treatment of cerebrovascular disease business through the conversion of Bolt Medical Co., Ltd. into a wholly owned subsidiary
First written in FY2023-Q3. 6 of 11 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「During the current fiscal year, classroom-based and user training was provided to more than 360 facilities and doctors nationwide in accordance with the Appropriate Use Guidelines established by the Japanese Society for Neuroendovascular Therapy (JSNET), and the product was used primarily in the treatment of cerebral aneurysms and intracranial stenosis.」
In the first year of sales, Bolt Medical provided training to more than 360 facilities and doctors nationwide for the Medilizer AGD System, advancing its clinical use and adoption. - 2026-05-15RestatedResults
「「Medilizer AGD システム」につきましては、2025年３月の保険収載および販売開始以降、医療現場への早期浸透を目指し、座学やハンズオントレーニング等を通じて、医療従事者の皆様に対する製品理解の促進に取り組んでおります。」
保険収載・販売開始後の医療現場への浸透施策を継続している。 - FY2026-H1RestatedAnnual report
「Medilizer AGD System, a cerebrovascular guide-assist device developed by Bolt Medical Co., Ltd., which the company acquired in December 2022 and for which domestic manufacturing and marketing approval was obtained in June 2024, was listed for reimbursement and launched for sale on 1 March 2025.」
The company continues to report the progress of Bolt Medical's cerebrovascular treatment business following its acquisition, including the Medilizer AGD System's reimbursement listing and launch. - FY2025AdvancedAnnual report
「The Medilizer AGD System, a guide-assistance device for cerebrovascular procedures that obtained domestic marketing approval in June 2024, was listed for reimbursement and launched on 1 March 2025.」
Bolt Medical's cerebrovascular treatment business progressed from obtaining domestic marketing approval to reimbursement listing and the start of sales following its acquisition. - FY2025-H1AdvancedAnnual report
「In addition, Bolt Medical Co., Ltd., which we acquired in December 2022, obtained domestic marketing approval in June 2024, and we continue to pursue the launch of products in the cerebrovascular treatment field.」
Bolt Medical obtained domestic marketing approval in June 2024 and continues to prepare for the launch of its cerebrovascular treatment products. - FY2024-Q3RestatedAnnual report
「In addition, through Bolt Medical Co., Ltd., which we acquired in December 2022, we are pursuing the launch of products in the cerebrovascular treatment field.」
Through Bolt Medical, which we acquired in December 2022, we continue to pursue the launch of products in the cerebrovascular treatment field. - FY2024-Q2RestatedAnnual report
「In addition, through Bolt Medical Co., Ltd., which we acquired in December last year, we are pursuing the launch of products in the cerebrovascular treatment field.」
Through Bolt Medical, which we acquired in December 2022, we continue to pursue the launch of products in the cerebrovascular treatment field. - FY2024-Q1RestatedAnnual report
「In addition, with a view to future growth, we are pursuing the launch of products in the cerebrovascular treatment field through Bolt Medical Co., Ltd., which we acquired in December last year.」
Through Bolt Medical, which we acquired in December 2022, we continue to pursue the launch of products in the cerebrovascular treatment field. - FY2023-Q3First statedAnnual report
「At a meeting of the Board of Directors held on 23 December 2022, the Company resolved to acquire all shares and stock acquisition rights issued by Bolt Medical Co., Ltd. and convert it into a consolidated subsidiary. Pursuant to this resolution, the Company entered into a share transfer agreement dated 26 December 2022 and acquired all of the shares on the same day.」
The Company acquired all shares of Bolt Medical, which conducts research, development and manufacturing of medical devices for endovascular treatment of cerebrovascular disease, bringing its voting rights ratio to 100%, including the shares already held. The acquisition cost was ¥2,857.494 million and goodwill was provisionally ¥2,726.389 million. The acquisition was described as a growth investment to expand cerebrovascular endovascular treatment products in Japan and overseas and achieve NEXT300.